A class action lawsuit has been commenced against Nymox Corp. and its board

A class action lawsuit has been commenced against Nymox Corp. and its board of directors on behalf of shareholders that purchased their shares between January 2011 and November 2014.

The allegation is that Nymox failed to disclose material information affecting the Phase 3 clinical trials for its proprietary drug NX-1207 for the treatment of benign prostatic hyperplastic (BPH).

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 – NYMX

NEW YORK, Dec. 11, 2014 – Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical {Nasdaq: NYMX} securities between January 31, 2011 and November 2, 2014.

For more information, click here:

http://zlk.9nl.com/nymox-pharmaceutical-nymx

The complaint alleges that Nymox failed to disclose material information affecting the Phase 3 clinical trials for its proprietary drug NX-1207 for the treatment of benign prostatic hyperplastic (BPH).

On November 2, 2014, Nymox disclosed that the Company's two Phase 3 studies had to be halted because the drug failed to meet its primary endpoints for efficacy. The following day,

Nymox disclosed to the market for the first time, among other things, the difficulties faced in enrolling men for the trials, and the subjective nature of the measurement of the drug's success.

If you suffered a loss in Nymox you have until January 26, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit **http://zlk.9nl.com/nymox-pharmaceutical-nymx**

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com